TIL-based Therapies Market by Roots Analysis

 Driven by the potential to confer sustained therapeutic effects and thereby facilitate prolonged periods of remission, TIL-based therapies have received significant financial support, and promising leads are poised to soon achieve blockbuster status

 

Roots Analysis has announced the addition of “TIL-based Therapies Market, 2021-2030” report to its list of offerings.

 

The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of drug developers engaged in the development of TIL-based therapies.

§  An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix assessing the relative experience of KOLs shortlisted based on their contributions in this field, and a schematic world map representation engaged in the development of TIL-based therapies.

§  Detailed profiles of therapies being evaluated in clinical stages (phase I/II or above).

§  An overview of key therapeutic areas that are being targeted by TIL-based therapies. It also includes an assessment of the opportunity across oncological disease indications.

§  An analysis of the partnerships that have been established in the recent past.

§  An analysis of investments that have been made into companies which have proprietary TIL-based products / technologies.

§  A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies.

§  An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies.

§  A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Target Indication

§  Acute Lymphoblastic Leukemia

§  Melanoma

§  Others

To request for sample report - https://www.rootsanalysis.com/reports/til-therapies-market/request-sample.html

 

§  Key Players

 

§  Key Geographical Regions 

§  North America

§  Europe

§  Asia Pacific

 

The research includes brief profiles, featuring an overview of the company, its financial information (if available), details related to its product(s), highlighting type of therapy and current development status, technology portfolio (if available), recent developments and manufacturing capabilities. 

§  Cellular Biomedicine Group

§  Iovnace Biotherapeutics

§  Lytix Biopharma

§  Phio Pharmaceuticals

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/til-therapies-market.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.     Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030

2.     CAR-T Cell Therapies Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030

3.     TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030

4.     Cell and Gene Therapy CROs Market: Industry Trends and Global Forecasts (2nd Edition), 2021-2030

5.     Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://medium.com/@RootsAnalysis

LinkedIn: https://medium.com/@RootsAnalysis

Twitter: https://medium.com/@RootsAnalysis

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

Comments

Post a Comment

Popular posts from this blog

The microbial contract biomanufacturing market is growing at a CAGR of 8.7%, claims {Roots Analysis}

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “ Microbial Contract Biomanufacturing Market, 2020-2030 ” report to its list of offerings.   Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various...
Read more

Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 by Roots Analysis

  Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 .”   The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing §   Elaborate profiles of some of the key...
Read more

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more